DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma
[Background]: Sarcomas represent an extensive group of malignant diseases affecting mesodermal tissues. Among sarcomas, the clinical management of chondrosarcomas remains a complex challenge, as high-grade tumours do not respond to current therapies. Mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes are among the most common mutations detected in chondrosarcomas and may represent a therapeutic opportunity. The presence of mutated IDH (mIDH) enzymes results in the accumulation of the oncometabolite 2-HG leading to molecular alterations that contribute to drive tumour growth., [Methods]: We developed a personalized medicine strategy based on the targeted NGS/Sanger sequencing of sarcoma samples (n = 6) and the use of matched patient-derived cell lines as a drug-testing platform. The anti-tumour potential of IDH mutations found in two chondrosarcoma cases was analysed in vitro, in vivo and molecularly (transcriptomic and DNA methylation analyses)., [Findings]: We treated several chondrosarcoma models with specific mIDH1/2 inhibitors. Among these treatments, only the mIDH2 inhibitor enasidenib was able to decrease 2-HG levels and efficiently reduce the viability of mIDH2 chondrosarcoma cells. Importantly, oral administration of enasidenib in xenografted mice resulted in a complete abrogation of tumour growth. Enasidenib induced a profound remodelling of the transcriptomic landscape not associated to changes in the 5 mC methylation levels and its anti-tumour effects were associated with the repression of proliferative pathways such as those controlled by E2F factors., [Interpretation]: Overall, this work provides preclinical evidence for the use of enasidenib to treat mIDH2 chondrosarcomas., Supported by the Spanish Research Agency/FEDER (grants PID2022-142020OB-I00; PID2019-106666RB-I00), the ISC III/FEDER (PI20CIII/00020; DTS18CIII/00005; CB16/12/00390; CB06/07/1009; CB19/07/00057); the GEIS group (GEIS-62); and the PCTI (Asturias)/FEDER (IDI/2021/000027)., Consorcio CIBERONC - CB16/12/00390 and Consorcio CIBERER–CB06/07/1009 and CB19/07/00057)]; the Spanish Group for Research on Sarcomas (GEIS) (grant GEIS-62 to R.R.); and the Plan de Ciencia Tecnología e Innovación del Principado de Asturias (PCTI)/FEDER (grant IDI/2021/000027 to R.R.). BG and DM were supported by Severo Ochoa predoctoral fellowships (Plan de Ciencia Tecnología e Innovación del Principado de Asturias/FEDER; grants BP- 20-046 and BP-21–084 respectively). CH was supported by a predoctoral fellowship from the Fundación Científca de la Asociación Española Contra el Cáncer (AECC)., Peer reviewed